Abstract
There are very few reports on the protective effect of artesunate (ARS) in ulcerative colitis (UC). This study focused on the efficacy of ARS on intestinal barrier, inflammatory response, and potential mechanism in dextran sulfate sodium (DSS)-induced ulcerative colitis in mice. The results suggested that ARS treatment markedly alleviated DSS-induced clinical symptoms by relieving body weight loss, the disease activity index (DAI) score, and preventing colonic shortening. HE staining and scanning electron microscope analysis revealed that ARS treatment significantly protected the integrity of intestinal barrier through alleviating DSS-induced erosion of surface epithelial cells, reduction of goblet cells, and destruction of the crypt accompanied with inflammatory cells infiltration. Immunofluorescence histochemical staining and western blot assay confirmed that ARS notably inhibited the loss of Muc2 and claudin-1 in mucosal layer with a relative higher level of Bcl-2/Bax ratio and, moreover, inhibited cleaved-caspase-3 expression in colon tissue. In addition, this study reconfirmed the anti-inflammatory function of ARS evidenced by remarkably suppressing the phosphorylation of nuclear factor-κBα (IκBα) and NF-κB p65 and the expression of IL-1β, IL-6, and TNF-α while enhancing IL-10 expression. Taken together, these data highlight that ARS has the protective effect on UC through maintaining the expression of intestinal mucosal barrier-related proteins, suppressing the apoptosis and inflammatory response. This study may facilitate to understand the action mechanism of ARS against UC.
Similar content being viewed by others
References
Fell, J.M., R. Muhammed, C. Spray, K. Crook, and R.K. Russell. 2016. Management of ulcerative colitis. Archives of Disease in Childhood 101 (5): 469–474.
Liu, Y., Q. Ye, Y. Liu, J. Kang, Y. Chen, and W. Dong. 2017. Schistosoma japonicum attenuates dextran sodium sulfate-induced colitis in mice via reduction of endoplasmic reticulum stress. World Journal of Gastroenterology 23 (31): 5700–5712.
Fatani, A.J., F.S. Alrojayee, M.Y. Parmar, H.M. Abuohashish, M.M. Ahmed, and S.S. Al-Rejaie. 2016. Myrrh attenuates oxidative and inflammatory processes in acetic acid-induced ulcerative colitis. Experimental and Therapeutic Medicine 12 (2): 730–738.
Russell, S.E., R.M. Horan, A.M. Stefanska, A. Carey, G. Leon, M. Aguilera, D. Statovci, T. Moran, P.G. Fallon, F. Shanahan, E.K. Brint, S. Melgar, S. Hussey, and P.T. Walsh. 2016. IL-36alpha expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immuonlogy 9 (5): 1193–1204.
Ordás, I., L. Eckmann, M. Talamini, D.C. Baumgart, and W.J. Sandborn. 2012. Ulcerative colitis. The Lancet 380 (9853): 1606–1619.
Camilleri, M., K. Madsen, R. Spiller, B.G. Van Meerveld, and G.N. Verne. 2012. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterology & Motility 24 (6): 503–512.
Merga, Y., B.J. Campbell, J.M. Rhodes, and Mucosal Barrier. 2014. Bacteria and inflammatory bowel disease: Possibilities for therapy. Digestive Diseases 32 (4): 475–483.
Vindigni, S.M., T.L. Zisman, D.L. Suskind, and C.J. Damman. 2016. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: A tripartite pathophysiological circuit with implications for new therapeutic directions. SAGE Publications, London, England pp.: 606–625.
Turner, J.R. 2009. Intestinal mucosal barrier function in health and disease. Nature Reviews Immunology 9 (11): 799–809.
Lechuga, S., and A.I. Ivanov. 2017. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864 (7): 1183–1194.
Yan, Y., M. Shao, Q. Qi, Y. Xu, X. Yang, F. Zhu, S. He, P. He, C. Feng, Y. Wu, H. Li, W. Tang, and J. Zuo. 2018. Artemisinin analogue SM934 ameliorates DSS- induced mouse ulcerative colitis via suppressing neutrophils and macrophages. Acta Pharmacologica Sinica 39: 1633–1644.
Shi, C., H. Li, Y. Yang, and L. Hou. 2015. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. Mediators of Inflammation 435713.
Hou, L., and H. Huang. 2016. Immune suppressive properties of artemisinin family drugs. Pharmacology & Therapeutics 166: 123–127.
Yang, Z., J. Ding, C. Yang, Y. Gao, X. Li, X. Chen, Y. Peng, J. Fang, and S. Xiao. 2012. Immunomodulatory and anti-inflammatory properties of Artesunate in experimental colitis. Current Medicinal Chemistry 19: 4541–4551.
Wirtz, S., and M.F. Neurath. 2007. Mouse models of inflammatory bowel disease. Advanced Drug Delivery Reviews 59 (11): 1073–1083.
Maxwell, J.R., W.A. Brown, C.L. Smith, F.R. Byrne, and J.L. Viney. 2009. Methods of inducing inflammatory bowel disease in mice. Current Protocols in Pharmacology Chapter 5: t5–t58.
Zhu, G., H. Wang, T. Wang, and F. Shi. 2017. Ginsenoside Rg1 attenuates the inflammatory response in DSS-induced mice colitis. International Immunopharmacology 50: 1–5.
Liu, S., Y. Liu, Q. Ma, S. Cui, and J. Liu. 2015. Expression and localization of cysteine sulfinate decarboxylase in major salivary glands of male mice. Archives of Oral Biology 60 (4): 615–621.
WIRTZ, S., and M. NEURATH. 2007. Mouse models of inflammatory bowel disease. Advanced Drug Delivery Reviews 59 (11): 1073–1083.
Williams, K.L., C.R. Fuller, L.A. Dieleman, C.M. DaCosta, K.M. Haldeman, R.B. Sartor, and P.K. Lund. 2001. Enhanced survival and mucosal repair after dextran sodium sulfate–induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 120 (4): 925–937.
Merga, Y., B.J. Campbell, and J.M. Rhodes. 2014. Mucosal Barrier, Bacteria and inflammatory bowel disease: Possibilities for therapy. Digestive Diseases 32 (4): 475–483.
Johansson, M.E., D. Ambort, T. Pelaseyed, A. Schutte, J.K. Gustafsson, A. Ermund, D.B. Subramani, J.M. Holmen-Larsson, K.A. Thomsson, J.H. Bergstrom, S. van der Post, A.M. Rodriguez-Pineiro, H. Sjovall, M. Backstrom, and G.C. Hansson. 2011. Composition and functional role of the mucus layers in the intestine. Cellular and Molecular Life Sciences 68 (22): 3635–3641.
Tytgat, K.M., H.A. Buller, F.J. Opdam, Y.S. Kim, A.W. Einerhand, and J. Dekker. 1994. Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. Gastroenterology 107 (5): 1352–1363.
J-W Van Klinken, B., J.-W.G. Van der Wal, A.W.C. Einerhand, H.A. Büller, and J. Dekker. 1999. Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut 44: 387–393.
Van der Sluis, M., B.A. De Koning, A.C. De Bruijn, A. Velcich, J.P. Meijerink, J.B. Van Goudoever, H.A. Buller, J. Dekker, I. Van Seuningen, I.B. Renes, and A.W. Einerhand. 2006. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131 (1): 117–129.
Yu, Q.H., and Q. Yang. 2009. Diversity of tight junctions (TJs) between gastrointestinal epithelial cells and their function in maintaining the mucosal barrier. Cell Biology International 33 (1): 78–82.
Singh, R., S. Chandrashekharappa, S.R. Bodduluri, B.V. Baby, B. Hegde, N.G. Kotla, A.A. Hiwale, T. Saiyed, P. Patel, M. Vijay-Kumar, M.G.I. Langille, G.M. Douglas, X. Cheng, E.C. Rouchka, S.J. Waigel, G.W. Dryden, H. Alatassi, H. Zhang, B. Haribabu, P.K. Vemula, and V.R. Jala. 2019. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nature Communications 10 (1).
Al-Sadi, R., M. Boivin, and T. Ma. 2009. Mechanism of cytokine modulation of epithelial tight junction barrier. Frontiers in Bioscience-Landmark 14: 2765–2778.
Suzuki, T. 2013. Regulation of intestinal epithelial permeability by tight junctions. Cellular and Molecular Life Sciences 70 (4): 631–659.
Chen, Y., M. Zhang, and F. Ren. 2019. A role of exopolysaccharide produced by Streptococcus thermophilus in the intestinal inflammation and mucosal Barrier in Caco-2 monolayer and dextran sulphate sodium-induced experimental murine colitis. Molecules 24 (3): 513.
Gitter, A.H., K. Bendfeldt, J.D. Schulzke, and M. Fromm. 2000. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. The FASEB Journal 14 (12): 1749–1753.
Heller, F., P. Florian, C. Bojarski, J. Richter, M. Christ, B. Hillenbrand, J. Mankertz, A.H. Gitter, N. Bürgel, M. Fromm, M. Zeitz, I. Fuss, W. Strober, and J.D. Schulzke. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2): 550–564.
Dong, J., H. Wang, J. Zhao, J. Sun, T. Zhang, L. Zuo, W. Zhu, J. Gong, Y. Li, L. Gu, and J. Li. 2015. SEW2871 protects from experimental colitis through reduced epithelial cell apoptosis and improved barrier function in interleukin-10 gene-deficient mice. Journal of Immunology Research 61 (3): 303–311.
Zhao, X., Z. Li, J. Wang, X. Xing, Z. Wang, L. Wang, and Z. Wang. 2015. Effects of chelated Zn/cu/Mn on redox status, immune responses and hoof health in lactating Holstein cows. Journal of Veterinary Science 16 (4): 439–446.
J. Chen, J. Lin, H, Luo, and M. Li. 2019. Effects of human Interleukin-10 on ventilator-associated lung injury in rats. Inflammation 42 (2) 538–547.
Hasnain, S.Z., S. Tauro, I. Das, H. Tong, A.C.H. Chen, P.L. Jeffery, V. McDonald, T.H. Florin, and M.A. McGuckin. 2013. IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology 144 (2): 357–368.
Xavier, R.J., and D.K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (7152): 427–434.
Choi, J.H., K.S. Chung, B.R. Jin, S.Y. Cheon, A. Nugroho, S.S. Roh, and H.J. An. 2017. Anti-inflammatory effects of an ethanol extract of Aster glehni via inhibition of NF-κB activation in mice with DSS-induced colitis. Food & Function 8: 2611–2620.
Kang, J., S. Choi, J.E. Jang, P. Ramalingam, Y.T. Ko, S.Y. Kim, and S.H. Oh. 2017. Wasabia japonica is a potential functional food to prevent colitis via inhibiting the NF- κB signaling pathway. Food & Function 8: 2865–2874.
Acknowledgments
This work was supported by the grants from National Natural Science Foundation (Nos. 31672595) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Author contributions
S. J. Yin, H. F. Yang, and J. G. Li designed the study. S. J. Yin and H. F. Yang performed the immunofluorescence staining and western blot experiments. S. M. Wei and L. H. Li help to perform the scanning electron microscope and HE staining. Y. Tao helps to perform the inflammatory cytokines assay. S. J. Yin and J.G. Li wrote the manuscript. Y. Tao and M. J. Liu reviewed the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yin, S., Yang, H., Tao, Y. et al. Artesunate ameliorates DSS-induced ulcerative colitis by protecting intestinal barrier and inhibiting inflammatory response. Inflammation 43, 765–776 (2020). https://doi.org/10.1007/s10753-019-01164-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-019-01164-1